Want to see DERM full AI Analyst Report?
DERM Stock Chart & Stats
$5.39
-$0.02(-0.58%)
At close: 4:00 PM EST
$5.39
-$0.02(-0.58%)
Day’s Range― - ―
52-Week Range$4.31 - $9.56
Previous CloseN/A
Volume25.59K
Average Volume (3M)296.62K
Market Cap
$192.74M
Enterprise Value$161.18M
Total Cash (Recent Filing)$27.22M
Total Debt (Recent Filing)$25.47M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding21,534,548
10 Day Avg. Volume196,071
30 Day Avg. Volume296,618
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)5.93
Price to Sales (P/S)3.05
P/FCF Ratio-15.18
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit4.13
Enterprise Value/Ebitda-111.77
Forecast
1Y Price Target
$14.00Price Target Upside159.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.07
Revenue Forecast (FY)$82.62M
Bulls Say, Bears Say
Bulls Say
Emrosi Revenue AccelerationA ~200% YoY jump and healthy sequential growth for Emrosi demonstrates durable product-market fit and scalable demand in dermatology. Sustained prescription momentum and improving refill rates create a compounding revenue base that supports multi-period top-line expansion as commercial coverage deepens.
Turn To Positive Adjusted EBITDATransitioning to positive adjusted EBITDA shows the business can achieve operating leverage as revenue scales and expenses remain controlled. Durable adjusted profitability reduces dependency on financing, validates commercial ROI, and is a key intermediate step toward sustainable GAAP profitability if margins and reimbursement hold.
Expanded Payer Access & Prescriber GrowthBroad GPO access and rising prescriber adoption materially increase addressable market reach and lower distribution friction. Combined with clinical publications and guideline citations, this structural access supports durable formulary inclusion, reduces reliance on copay support, and underpins steady long-term uptake.
Bears Say
Ongoing GAAP LossesPersistent GAAP net losses mean adjusted profitability hasn't yet translated to full accounting profitability. Continued GAAP deficits can constrain reinvestment, require external financing to fund growth, and signal structural margin shortfalls until scale, ASP stability, and payer reimbursement improve materially.
Weak Cash GenerationNegative TTM operating and free cash flow highlight a deterioration in cash generation and raise reliance on external capital. Coupled with a meaningful rise in leverage, weaker cash flow reduces strategic flexibility for commercialization, increases refinancing risk, and elevates sensitivity to margin or reimbursement setbacks.
Concentration On EmrosiHigh dependence on a single recently launched brand concentrates execution, reimbursement, and market-risk on Emrosi. If payer quality coverage, ASPs, or refill dynamics falter, company-wide results and margins could be disproportionately affected, while legacy integration actions signal additional product/portfolio execution risk.
Journey Medical Corp News
DERM FAQ
What was Journey Medical Corp’s price range in the past 12 months?
Journey Medical Corp lowest stock price was $4.31 and its highest was $9.55 in the past 12 months.
What is Journey Medical Corp’s market cap?
Journey Medical Corp’s market cap is $192.74M.
When is Journey Medical Corp’s upcoming earnings report date?
Journey Medical Corp’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were Journey Medical Corp’s earnings last quarter?
Journey Medical Corp released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.088 by $0.008.
Is Journey Medical Corp overvalued?
According to Wall Street analysts Journey Medical Corp’s price is currently Undervalued.
Does Journey Medical Corp pay dividends?
Journey Medical Corp does not currently pay dividends.
What is Journey Medical Corp’s EPS estimate?
Journey Medical Corp’s EPS estimate is -0.05.
How many shares outstanding does Journey Medical Corp have?
Journey Medical Corp has 21,534,548 shares outstanding.
What happened to Journey Medical Corp’s price movement after its last earnings report?
Journey Medical Corp reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.088. Following the earnings report the stock price went up 22.351%.
Which hedge fund is a major shareholder of Journey Medical Corp?
Currently, no hedge funds are holding shares in DERM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Journey Medical Corp Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (159.74% Upside)
$14.00 (159.74% Upside)
Blogger Sentiment
Bullish
DERM Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.76%
12-Months-Change
Fundamentals
Return on Equity
-35.57%
Trailing 12-Months
Asset Growth
7.74%
Trailing 12-Months
Company Description
Journey Medical Corp
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
DERM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for Emrosi and meaningful financial improvement: robust revenue growth (total revenue +21% YoY; Emrosi revenue +~200% YoY), rising prescription volumes and prescriber counts, swing to positive adjusted EBITDA, and improved cash balance. Key execution wins include contracts with the three major PBM-affiliated GPOs and expanding clinical validation. Remaining execution items and risks include gross-margin pressure from a one-time API write-down, variability in revenue-per-script/ASP as payer coverage matures, limited current quality coverage (single-step or better ~34% of commercial lives), and an ongoing GAAP net loss. Overall, positive operational and financial trajectory but with clear near-term tasks on payer adoption and margin stability.View all DERM earnings summariesDERM Stock 12 Month Forecast
Average Price Target
$14.00
▲(159.74% Upside)
Technical Analysis
Ownership Overview
20.11% Insiders
14.62% Mutual Funds
0.89% Other Institutional Investors
58.80% Public Companies and
Individual Investors